Mirum Pharmaceuticals (MIRM) Provides Development Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Citi Reiterates Buy Rating on Mirum (MIRM), PT $34, 'Volixibat ICP Trial Discontinued, PSC and PBC Readouts Remain On Track'
November 29, 2022 9:05 AM ESTCiti analyst David Lebowitz reiterated a Buy rating and $34.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today, Mirum announced the discontinuation of Phase IIb OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to challenges in... More
